Further pilot studies with increased participant numbers, including international participants, will allow for more detailed data analysis of results and a requirement to report test interpretation would be of additional value as an educational tool for laboratories for the diagnosis of Strongylodiasis.
Conclusion
Introduction of a Strongyloides EQA would enable ongoing review and improvement in the quality of results, particularly when reporting low level positive specimens with result values close to the clinical cut-off value for Strongyloidiasis.
Background
Strongyloidiasis is an infectious disease caused by the parasitic roundworm Strongyloides stercoralis. In immunocompromised individuals, Strongyloides infection can be fatal. Strongyloidiasis is endemic in tropical and subtropical regions, however there is a worldwide distribution with an estimated 370 million people affected due to global migration patterns 
Methods
The Strongyloides pilot survey was distributed to 10 Australian and New Zealand laboratories for Strongyloides IgG testing as per routine laboratory protocols. Four serum specimens of human origin were distributed in one survey. Specimen 1 was a positive neat sample; Specimens 2 and 4 were positive pooled samples and Specimen 3 was a negative neat sample. Qualitative (positive/negative) and quantitative (OD, Index and S/CO) data was analysed. Assigned results were determined by a consensus of ≥ 80% for qualitative data. Quantitative data analysis was performed by converting all result values to the same unit (S/CO) and robust statistics performed for the positive samples using in-house RCPAQAP statistical software.
Results

All 10 participants returned results for the 4 specimens. Participants tested for
Strongyloides IgG using a commercial enzyme-linked immunosorbent assay (ELISA) or an In-house assay. Two commercial assays and one In-house assay were used for testing in this survey (Figure 1 ). 
